Recent data show that B cells and plasma cells located in tumours or in tumour-draining
lymph nodes can have important roles in shaping antitumour immune responses. In tumour …

A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …

Despite decades of research, efforts to directly target KRAS have been challenging.
MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that …

Tissues are organized in cellular niches, the composition and interactions of which can be
investigated using spatial omics technologies. However, systematic analyses of tissue …

Purpose: Although clinical studies have shown promise for targeting programmed cell death
protein-1 (PD-1) and ligand (PD-L1) signaling in non–small cell lung cancer (NSCLC), the …

Importance Checkpoint inhibitors have replaced docetaxel as the new standard second-line
therapy in advanced non–small cell lung carcinoma (NSCLC), but little is known about the …

KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS
inhibitors has renewed interest in this molecular variant. Different KRAS mutations may …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

Purpose: By unlocking antitumor immunity, antibodies targeting programmed cell death 1
(PD-1) exhibit impressive clinical results in non–small cell lung cancer, underlining the …

Fibroblasts are poorly characterised cells that variably impact tumour progression. Here, we
use single cell RNA-sequencing, multiplexed immunohistochemistry and digital cytometry …